Lanean...
The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer
Lung cancer is the most common cancer and leading cause of cancer death. While targeted therapies have redefined treatment options for non-small cell lung carcinoma (NSCLC) with genetic aberrations such as epidermal growth factor and anaplastic lymphoma kinase, many patients do not harbour these onc...
Gorde:
| Argitaratua izan da: | Ther Adv Med Oncol |
|---|---|
| Egile Nagusiak: | , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
SAGE Publications
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6716180/ https://ncbi.nlm.nih.gov/pubmed/31497071 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835919870360 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|